1. Based on the literature, the pancreatic cancer treatment predictor biomarker, which is used in the domestic clinical field, is actually applied to the pancreatic cancer patient cohort of the National Cancer Center. 2. To systematically prospectively identify prospective treatment response biomarkers for Pancreatic Cancer Cohort in the National Cancer Center
1. Immunohistochemistry and gene test for hENT1, DCK, SMAD4, CES2, BRCA 1/2,PALB2, MMRd, MSI, Tumor Ag and etc. on Cancer sample 2. Collect data of Biomarker for pancreatic cancer 3. Compare with Big data and Cohort study in National cancer center 4. The number of subjects is changed by statistical consideration. 218-\>238
Study Type
OBSERVATIONAL
Enrollment
238
NATIONAL CANCER CENTER 323, Ilsan-ro, Ilsandong-gu,
Goyang-si, Gyeonggi-do, South Korea
median survival
The length of time from either the date of diagnosis or the start of treatment for a disease,the length of time during and after the treatment of a disease, such as cancer, that a patient lives with the disease but it does not get worse
Time frame: 5 years
progressive-free survival
The length of time during and after the treatment of a disease, such as cancer, that a patient lives with the disease but it does not get worse
Time frame: 5 years
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.